As a soluble guanylate cyclase (sGC) stimulant, Riociguat Tablets (Adempas) provide an innovative therapeutic option for the treatment of specific types of pulmonary arterial hypertension.
Indications for Riociguat Tablets (Adempas)
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) that remains after surgical treatment.
Patients with inoperable CTEPH.
The treatment goal is to improve exercise tolerance and WHO functional class.
Pulmonary Arterial Hypertension (PAH)
Indicated for adult patients with pulmonary arterial hypertension (WHO Group 1).
Improves exercise capacity.
Enhances WHO functional class.
Delays the progression of clinical deterioration.
Specifications and Properties of Riociguat Tablets (Adempas)
Specifications
Available in 5 precise dosage strengths, all featuring a round, biconvex shape.
0.5 mg: White tablets, engraved with the "BAYER" cross and the marking "0.5R".
1 mg: Light yellow tablets, engraved with the "BAYER" cross and the marking "1R".
1.5 mg: Orange-yellow tablets, engraved with the "BAYER" cross and the marking "1.5R".
2 mg: Light orange tablets, engraved with the "BAYER" cross and the marking "2R".
2.5 mg: Red-orange tablets, engraved with the "BAYER" cross and the marking "2.5R".
Dosage Form Adaptability Design
The tablets can be crushed and mixed with water or soft foods (e.g., applesauce) for administration.
Preparation must be done immediately before taking the medication.
Storage Conditions for Riociguat Tablets (Adempas)
Core Storage Parameters
Standard storage temperature: 25°C (77°F).
Allowable temperature fluctuation range: 15°C - 30°C (59°F - 86°F).
The original packaging must be kept intact and sealed.
Special Precautions
Avoid storage in environments with high temperature, high humidity, or direct sunlight.
Store in a safe area that is out of the reach of children.
